Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Pilot Study of Losmapimod to Evaluate the Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments in Subjects With Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) With Extension

Next Previous
X
Search
Trial Profile

An Open-Label Pilot Study of Losmapimod to Evaluate the Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments in Subjects With Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) With Extension

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Losmapimod (Primary)
  • Indications Facioscapulohumeral muscular dystrophy
  • Focus Adverse reactions
  • Acronyms FSHD
  • Sponsors Fulcrum Therapeutics

    • Most Recent Events

    • 02 Dec 2024 Status changed from active, no longer recruiting to discontinued. ( Sponsor Decision )
    • 15 Jul 2024 Results (n=14) from the main portion of the study, assessing the safety, tolerability and changes in biomarker and clinical outcome assessments in patients with FSHD1, published in the Journal of the Neurological Sciences
    • 05 Jul 2023 Planned End Date changed from 1 Jan 2024 to 1 Jan 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top